---
title: "Retatrutide: What We Know From Phase 2 Trials"
url: https://www.bodyhackguide.co/blog/retatrutide-phase-2-trials-review
description: "Breaking down the Phase 2 clinical trial data for Retatrutide (LY3437943), the triple GIP/GLP-1/glucagon receptor agonist showing unprecedented weight loss"
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

Research 2 min read Mar 17, 2026 Fact-checked (https://www.bodyhackguide.co/editorial-standards)

# Retatrutide: What We Know From Phase 2 Trials

Breaking down the Phase 2 clinical trial data for Retatrutide (LY3437943), the triple GIP/GLP-1/glucagon receptor agonist showing unprecedented weight loss results.

B

BodyHackGuide Team

Key Takeaway

## What is Retatrutide?\n\nRetatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly targeting three receptors simultaneously:\n\n1. **GIP receptor** (Glucose-dependent insulinotropic polypeptide)\n2. **GLP-1 receptor** (Glucagon-like peptide-1)\n3. **Glucagon receptor**\n\n## Phase 2 Trial Results\n\nThe Phase 2 trial (published in NEJM, 2023) enrolled 338 participants with obesity.\n\n### Key Findings\n\n- **24-week results:** Up to 17.5% body weight loss\n- **48-week results:** Up to 24.2% body weight loss at the 12mg dose\n- **Dose-dependent:** Higher doses showed greater efficacy\n\n### Dosing Groups\n\n| Dose | 24-Week Loss | 48-Week Loss |\n|------|-------------|-------------|\n| 1mg | -7.2% | -8.7% |\n| 4mg | -12.9% | -17.1% |\n| 8mg | -14.5% | -22.8% |\n| 12mg | -17.5% | -24.2% |\n\n## How It Compares\n\n- **Semaglutide (Wegovy):** ~15% at 68 weeks\n- **Tirzepatide (Mounjaro):** ~22.5% at 72 weeks\n- **Retatrutide:** ~24.2% at just 48 weeks\n\n## Mechanism Advantage\n\nThe triple-agonist approach may explain the superior results:\n\n- GLP-1: Appetite suppression and insulin sensitization\n- GIP: Enhanced incretin effect and fat metabolism\n- Glucagon: Increased energy expenditure and hepatic fat reduction\n\n## Side Effects\n\nMost common adverse events were GI-related:\n- Nausea (most common, typically transient)\n- Diarrhea\n- Vomiting\n- Constipation\n\n## Current Status\n\nRetatrutide is currently in Phase 3 clinical trials. FDA approval is not expected before 2026-2027.\n\n## What This Means for Research\n\nThe triple-agonist approach represents a new frontier in metabolic peptide research, potentially offering superior efficacy compared to dual-agonists like tirzepatide.

## Related Articles

Research

### BPC-157 vs TB-500: Head-to-Head Comparison for Recovery

Read
https://www.bodyhackguide.co/blog/bpc-157-vs-tb-500

Research

### Glutathione (GSH): What the Research Actually Supports

Read
https://www.bodyhackguide.co/blog/glutathione-research-guide

Research

### Aquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For

Read
https://www.bodyhackguide.co/blog/aqasome-nanotechnology-oral-peptides

## New guides, by email

New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime.

No spam. Unsubscribe anytime.

Share this article: 𝕏 / Twitter (https://twitter.com/intent/tweet?text=Retatrutide%3A%20What%20We%20Know%20From%20Phase%202%20Trials&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Fretatrutide-phase-2-trials-review)

BT

BodyHackGuide Team (https://www.bodyhackguide.co/about)Founder & Lead Researcher

Founder of BodyHackGuide. Writes the site's guides on peptide research, nootropics and vendor quality, and posts as u/BioChonch on Reddit.

Join r/BodyHackGuide on Reddit: https://reddit.com/r/bodyhackguide
Join Discord: https://discord.gg/Mhq5UdRYBA
|
About the author: https://www.bodyhackguide.co/about

## Discussion

Sign in to join the discussion

No comments yet. Be the first to share your thoughts!

Back to all articles: https://www.bodyhackguide.co/blog

BodyHackGuide (https://www.bodyhackguide.co/)

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved.

- Terms: https://www.bodyhackguide.co/terms
- Privacy: https://www.bodyhackguide.co/privacy

## Structured data

```json
[
  {
    "@context": "https://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
      {
        "@type": "ListItem",
        "position": 1,
        "name": "Home",
        "item": "https://www.bodyhackguide.co/"
      },
      {
        "@type": "ListItem",
        "position": 2,
        "name": "Blog",
        "item": "https://www.bodyhackguide.co/blog"
      },
      {
        "@type": "ListItem",
        "position": 3,
        "name": "Retatrutide: What We Know From Phase 2 Trials"
      }
    ]
  },
  {
    "@context": "https://schema.org",
    "@type": "BlogPosting",
    "headline": "Retatrutide: What We Know From Phase 2 Trials",
    "description": "Breaking down the Phase 2 clinical trial data for Retatrutide (LY3437943), the triple GIP/GLP-1/glucagon receptor agonist showing unprecedented weight loss results.",
    "datePublished": "2026-03-17T12:48:16.095648+00:00",
    "dateModified": "2026-03-17T12:48:16.095648+00:00",
    "author": {
      "@type": "Person",
      "name": "BodyHackGuide Team"
    },
    "reviewedBy": {
      "@type": "Person",
      "name": "BodyHackGuide Team"
    },
    "publisher": {
      "@type": "Organization",
      "name": "BodyHackGuide",
      "url": "https://www.bodyhackguide.co",
      "logo": {
        "@type": "ImageObject",
        "url": "https://www.bodyhackguide.co/bhglogo.png"
      }
    },
    "mainEntityOfPage": "https://www.bodyhackguide.co/blog/retatrutide-phase-2-trials-review",
    "wordCount": 213,
    "timeRequired": "PT2M",
    "articleSection": "Research",
    "inLanguage": "en-US",
    "isAccessibleForFree": true,
    "speakable": {
      "@type": "SpeakableSpecification",
      "cssSelector": [
        "h1",
        ".blog-tldr",
        "article p:first-of-type"
      ]
    }
  },
  {
    "@context": "https://schema.org",
    "@type": "Organization",
    "@id": "https://www.bodyhackguide.co#organization",
    "name": "BodyHackGuide",
    "alternateName": "BHG",
    "url": "https://www.bodyhackguide.co",
    "logo": {
      "@type": "ImageObject",
      "url": "https://www.bodyhackguide.co/logo.png",
      "width": 512,
      "height": 512
    },
    "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.",
    "foundingDate": "2024",
    "founder": {
      "@id": "https://www.bodyhackguide.co/about#person"
    },
    "sameAs": [
      "https://reddit.com/r/BodyHackGuide",
      "https://reddit.com/r/BrainHackGuide",
      "https://reddit.com/r/Biohackingher",
      "https://discord.gg/Mhq5UdRYBA"
    ],
    "knowsAbout": [
      "Peptide research",
      "Nootropic research",
      "Biohacking",
      "Compound dosing",
      "Vendor transparency"
    ],
    "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards",
    "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards",
    "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards"
  }
]
```